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A 29 year old multiparous Hispanic female presented to our routine
obstetrical clinic at 7 weeks gestation. She had a past medical history
signiﬁcant for morbid obesity and poorly controlled type 2 diabetes
mellitus with a hemoglobin A1C of 10.7. On physical exam, the patient
was noted to have a left breast mass at the 11 o'clock position. Other-
wise both breasts appeared symmetrical with no signs of skin changes
or lymphadenopathy. Similarly, both nipples and areola had no abnor-
mal ﬁndings. A breast ultrasound was performed and demonstrated a
4.5 × 2.6 × 3.2 cm mass that was irregular and hypoechoic consistent1. Introduction
Pregnancy-associated breast cancer is deﬁned as breast cancer diag-
nosed during pregnancy or in the ﬁrst postpartum year. It is the most
common cause of invasive cancer in pregnant women and is estimated
to occur at a rate of 6.5 per 100,000 live births [1,2]. According to a case–
control study from Princess Margaret Hospital, pregnant patients are at
higher risk for presenting with advanced disease because pregnancy
impedes early detection [3]. Risk factors for pregnancy-associated
breast cancer include early age of menarche, nulliparity, personal histo-
ry of breast cancer, advancedmaternal age, family history of breast can-
cer, increased consumption of alcohol, obesity and a sedentary lifestyle
[4]. Of interest to Obstetricians is the management of breast cancer in
pregnancy. The timing of delivery should take into account maternal
and fetal status as well as need for further chemotherapy and expected
perinatal outcomewhile themode of delivery should be determined by
standard obstetrical indications [5]. In an article by Trichopoulos et al.,
full term births over the age of 35 years had an increased risk in the de-
velopment of breast cancer; uniparous women were observed to have
an elevated risk of breast cancer soon after delivery, speciﬁcally those
women who are 30 years or older at the time of their ﬁrst delivery [6].
We present a case of premenopausal invasive ductal carcinoma of the
breast diagnosed during pregnancy, and review the literature regarding
the antenatal management of breast cancer.cine, Dept. of Obstetrics and
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. This is an open access article underwith BIRADS 4 classiﬁcation. A core needle biopsy was performed and
revealed invasive ductal carcinoma that was estrogen and progesterone
receptor positive andHER2 negative. The patient underwent a left mod-
iﬁed radical mastectomy with left axillary lymph node dissection. Final
pathology conﬁrmed invasive ductal carcinoma of the left breast, staged
at T3N2MX with ER and PR positivity in 80% and 70% of the tumor cells
respectively. The patient was treated with a combination of 4 cycles of
doxorubicin and cyclophosphamideduring the second and third trimes-
ter. At 37 weeks gestation she was diagnosed with preeclampsia
and underwent delivery. A repeat cesarean section along with a risk-
reducing bilateral salpingo-oophorectomy was performed. Postopera-
tively a chest and abdomino-pelvic computed tomography as well as a
brain MRI were performed and showed no evidence of metastases.
Weekly paclitaxel was started on post-operative day 7 and was contin-
ued for 3 months.
The patient has also completed radiation to the chest wall and nodal
areas. Currently, the patient has completed 12 cycles of paclitaxel and
4 cycles of doxorubicin & cyclophosphamide. A CT of the chest, abdo-
men and pelvis was performed and revealed no evidence of disease.
BRCA testing is pending.2. Discussion
The care of a pregnant patient with breast cancer involves the utili-
zation of a multidisciplinary team, including a geneticist, obstetrician,
maternal–fetal medicine specialist, medical oncologist, surgical oncolo-
gist and neonatologist. Early ultrasound dating should be obtained in
order to provide adequate counseling regarding pregnancy manage-
ment. In addition, a detailed fetal anatomic evaluation during the mid
second trimester is recommended to exclude pre-existing fetal anomalies
[4]. The safest interval for most cancer therapies in pregnancy is between
the second and third trimesters, avoiding induction of teratogenic risks or
miscarriages [4]. If growth restriction or non-reassuring fetal status isthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Chemotherapy: Maternal and fetal effects, JOGC [23].
Agent Maternal Fetal
Alkylating agents:
Cyclophosphamide
Myelosupression First trimester exposure: Oculofacial abnormalities, missing digits, nail malformations, coronary artery defects,
umbilical hernia, hemangioma, imperforate anus, rectovaginal ﬁstula, cleft palet, microcephaly, growth
restriction, developmental delays
Second trimester exposure: growth restriction, microcephaly, neonatal pancytopenia
Melphalan Myelosuppresion, ovarian failure,
amenorrhea
No link with congenital defects
Taxanes: Paclitaxel Myelosuppression, Neurotoxicity Few case reports of fetal exposure: no reported defects
Trastuzumab
(Herceptin)
Cardiac dysfunction, arrhythmias Decreased amniotic ﬂuid, kidney defects
Vinblastine Myelosuppression, Neurotoxicity First trimester: normal outcomes, with three reported cases of suspected teratogenicity with hydrocephalus
after ﬁrst trimester exposure, cleft lip/palate
Vinorelbine Myelosuppression Sparse data available
5-Fluorouracil Myelosuppresion, mucositis,
diarrhea, hand-foot syndrome
First trimester: Radial dysplasia, absent digits, hypoplasias of thoracic and abdominal organs such as lungs,
aorta, esophagus, duodenum, ureters
Methotrexate Myelosuppresion, acute renal failure First trimester: cephalic and skull abnormalities, absence of frontal bones, hypertelorism, depressed or
widened nasal bridge, hypoplasia of the mandible, heart defects, absence of digits
Doxorubicin Myelosuppresion, cardiac toxicity First trimester: Imperforate anus, rectovaginal ﬁstula, microcephaly
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obstetrical guidelines. The timing of delivery should take into account
maternal and fetal status as well as need for further chemotherapy
and expected perinatal outcome, while the mode of delivery should
be determined by standard obstetrical indications [5]. Chemotherapy
during pregnancy should not be given within 3 weeks of planned
delivery in order to avoid problems associated with maternal and
fetal myelosuppression [12–14]. Chemotherapy and radiation may be
started immediately following a vaginal delivery and one week after
cesarean section [7]. Breastfeeding is contraindicated during treatment
with chemotherapy or radiation therapy [7].
If breast cancer is discovered during pregnancy, diagnostic and stag-
ing evaluations can be modiﬁed to limit fetal exposure [8]. The search
for distant metastases may be performed using ultrasonography and
MRI [8]. Mastectomy may be performed without fetal injury or sponta-
neous abortion [8]. Generally breast surgeons prefer to wait until after
the ﬁrst trimester due to the increased risk of spontaneous abortion as-
sociated with ﬁrst trimester surgical intervention, although women
who undergo surgery for breast cancer in the ﬁrst trimester do not
seem to have a higher rate of spontaneous loss compared with the
general population [9]. Bothmastectomy and breast-conserving surgery
with axillary lymph node dissection are surgical options for pregnancy-
associated breast cancer [8]. Mastectomy is sometimes preferred for
breast cancer in pregnancy since follow-up radiation therapy is typically
not required post-operatively.
Isosulfan blue or methylene blue dye lymph node mapping is not
recommended in pregnant women because anaphylaxis has been ob-
served [8]. Technetium-based sentinel node identiﬁcation, however,
has been performed safely in pregnancy [8]. Doxorubicin and cyclo-
phosphamide (AC regiment) as well as 5-ﬂuorouracil, doxorubicin,
and cyclophosphamide (FAC regimen) may be administered during
the second and third trimesters for pregnancy-associated breast cancer;
Hahn et al. reported on 40 cases of fetuses exposed to the FAC regimen
and found that all women delivered live births and only 3 had congen-
ital malformations [9].
In addition, Cardonick et al. reviewed 104 patients that received an-
tenatal chemotherapy for breast cancer and demonstrated a 3.8% birth
defect rate [9]. Taxanes may also be used in pregnancy; Mir et al. pub-
lished a systematic review of 40 patients regarding taxane use in preg-
nancy and only reported one case of pyloric stenosis [10]. For patients
with hormone receptor negative breast cancer, dose-dense chemother-
apy regimens have demonstrated improved disease-free survival over
conventional dose chemotherapy in non-pregnant patients. Currently,however, the data on dose-dense chemotherapeutic agents in pregnan-
cy is limited and should not be administered for pregnancy-associated
breast cancer; Trastuzumab is a well-known treatment for HER2-posi-
tive breast cancer. However, if trastuzumab must be used, it should be
administered for as short of a duration as possible and surveillance of
amniotic ﬂuid levels and fetal growth should be performed [11] due to
risk for oligohydramnios. Data regarding the safety of Trastuzumab in
pregnancy is lacking. Therapy with selective estrogen receptormodula-
tors, such as tamoxifen, in patients with hormone receptor positive
pregnancy-associated breast cancer should be deferred until after deliv-
ery due to risks associated with craniofacial malformations and ambig-
uous genitalia [12]. Supportive oncological agents such as ondansetron,
promethazine granulocyte colony-stimulating growth factor and eryth-
ropoietin may be safely administered during pregnancy (Table 1).
The prognostic outcome in women diagnosed with breast cancer
during pregnancy is conﬂicting. Rodriquez et al. reviewed 797 patients
with pregnancy-associated breast cancer and compared them to 4177
non-pregnant breast cancer controls [15]; after controlling for stage of
disease, size of tumor, hormone receptor status, age, race, and type of
surgery, pregnancy-associated breast cancer survival was worse com-
pared to the non-pregnant breast cancer cohort. On the other hand,
Beadle et al. evaluated 652 women with pregnancy-associated breast
cancer and found no statistically signiﬁcant difference in rates of recur-
rence, distant metastasis or overall survival compared to women who
did not have pregnancy-associated breast cancer [16].
Both prospective case–control and cohort studies have reported a
20%–40% decreased risk of breast cancer in premenopausal obese
patients compared to normal weight controls [17,18–20]. Recently,
however, Cecchini et al. reported data taken from the Breast Cancer Pre-
vention Trial (BCPT) that showed that an increased risk of invasive
breast cancer was noted in overweight and obese premenopausal pa-
tients compared to patients of normal weight [21]. In addition, they
found only a slightly increased risk of invasive breast cancer among
the overweight and obese postmenopausal women in both the BCPT
and the Study of Tamoxifen and Raloxifene (STAR) trials. The potential
of obesity to mitigate breast cancer risk in both premenopausal and
postmenopausal patients seems to be inﬂuenced by hormone receptor
status; for example, a stronger inverse association between obesity
and premenopausal estrogen and progesterone receptor positive
(ER+/PR+) breast cancer has been observed compared to ER-/PR-
cases [19]. Yang et al. recently found that obesity was more frequent-
ly associated with receptor ER-/PR- breast cancer compared with
receptor positive disease in women 50 years old or younger but
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breast cancers [22].
3. Conclusion
An awareness of risk factors for the development of breast cancer in
pregnant patients is critical to early diagnosis and treatment of breast
cancer. A breast exam should be performed early in pregnancy if possi-
ble, and if exam is performed later in pregnancy, one should exercise
vigilance regarding ﬁndings. A careful review of chemotherapeutics
and their maternal as well as fetal effects should be instituted in a
new diagnosis of breast cancer, with close coordination of care among
specialists with the patient.
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